secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-08-14T19:20:31+00:00
Accession:  0001493152-26-038258
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics Q2 net loss widens to $5.2M; raises going-concern doubt
---------------------------------------------------------------------

- Q2 2026 net loss $5.2M vs $1.9M YoY; six-month loss $1.7M vs $4.1M; revenue $135.6K vs $6.6K.
- HCW9302 Phase 1: all 3 patients in 3 µg/kg cohort showed ≥25% SALT score reduction; no dose-limiting toxicities; full readout Q4 2026.
- Re-acquired ex vivo rights to HCW9206 from AlloTera; pursuing partner for CAR-T reagent market.
- Raised $5.6M in May/July private placements; officers/directors participated.
- Company expresses substantial doubt about going concern for next 12 months; Nasdaq compliance regained but monitor possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226038258/0001493152-26-038258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226038258/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-038258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer